Volanesorsen

Phase 3RNA therapy

Volanesorsen is a rna therapy that works as Apoc-III Antisense.[2] It is being investigated across 4 indications, with its most advanced program in Phase 3.[1]

Volanesorsen is one of 85 aso programs targeting Familial Partial Lipodystrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial Partial LipodystrophyActive, not recruiting

Hereditary Transthyretin AmyloidosisActive, not recruiting

HypercholesterolemiaUnknown

HypertriglyceridemiaActive, not recruiting

Familial Partial LipodystrophyPhase 2/Phase 3

Active, not recruiting

Hereditary Transthyretin AmyloidosisPhase 3

Active, not recruiting

HypercholesterolemiaPreclinical

Unknown

HypertriglyceridemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

130 competitors in Hypercholesterolemia

#DrugCompanyPhaseTrials

Avapro

Sanofi

Phase 3

1 2

Micardis

Boehringer Ingelheim

Phase 3

1 3

Comparator: Statins

Merck & Co.

Phase 3

3 4

Comparator: Pbo

Merck & Co.

Phase 3

2 5

Evacetrapib

Eli Lilly

Phase 3

2 6

Kynamro

KKastle Therapeutics, LLC

Phase 3

1 7

Enlicitide

Merck & Co.

Phase 3

3 8

Anacetrapib

Merck & Co.

Phase 3

1 9

Volanesorsen

AAkcea Therapeutics

Phase 3

6 10

Lapaquistat Acetate

Takeda

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Familial Chylomicronemia Syndrome3 trials

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 3·NCT02211209·67 enrolled

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Completed·AAkcea Therapeutics·Phase 3·NCT02658175·68 enrolled

Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

No longer available·AAkcea Therapeutics··NCT03544060

Hypertriglyceridemia1 trial

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 3·NCT02300233·114 enrolled

Cardiac Repolarization1 trial

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Completed· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 1·NCT02910635·52 enrolled

Familial Partial Lipodystrophy1 trial

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Terminated·AAkcea Therapeutics·Phase 2/3·NCT02527343·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Volanesorsen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Volanesorsen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Volanesorsen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akcea Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Apoc-III Antisense[2]
Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: AAkcea Therapeutics

Volanesorsen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Familial Chylomicronemia Syndrome3 trials

Hypertriglyceridemia1 trial

Cardiac Repolarization1 trial

Familial Partial Lipodystrophy1 trial

References

Drug Info

Quick Facts

Related News